Predicting progression in Primary Progressive Multiple Sclerosis with Machine Learning

Lead Investigator: Ryan Mizell, Advent Health
Title of Proposal Research: Predicting progression in Primary Progressive Multiple Sclerosis with Machine Learning
Vivli Data Request: 8768
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Multiple Sclerosis (MS) is a neurological disease without cure that affects nearly three million people globally. In MS, the immune system mistakenly attacks myelin, the coating that protects the nerves of the central nervous system. Myelin helps messages travel quickly from the brain to other parts of the body, so damage can cause a variety of symptoms such as visual changes, weakness, and imbalance. Most of patients who are diagnosed with MS have relapsing-remitting MS (RRMS), a form that mainly encompasses attacks on the brain or spinal cord termed relapses. Primary progressive multiple sclerosis (PPMS) is a type of MS where patients will gradually worsen over time, called progression.

Although numerous medications are available for the treatment of relapsing forms of MS, only Ocrelizumab (Ocrevus) has been shown to slow progression in PPMS. Ocrelizumab is a treatment which targets the B cells, an immune cell, to prevent further damage to the myelin of the central nervous system. Ocrelizumab is not effective in all patients with PPMS, and patients may continue to become worse over time despite treatment.

Presently, it is not clear why some patients continue to become worse while on treatment with Ocrelizumab. Research is ongoing to find effective treatments for PPMS, though no medication has since shown to be effective in preventing progression in PPMS. Further investigation is warranted to assess if there are predictors available for disease progression. In this study we will develop a model to predict the response to Ocrevus in patients with PPMS. The results of this study will aid in determining what factors influence treatment response and could help guide future therapeutic investigations.

Requested Studies:

A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Data Contributor: Roche
Study ID: NCT01194570
Sponsor ID: WA25046